Centering discussion on a patient profile of HER2+ gastric cancer, experts in oncology discuss the occurrence of neutropenia with trastuzumab deruxtecan therapy.
MRI Guidance Can Tailor Neoadjuvant Chemo for HR-/HER2+ Breast Cancer
The duration of neoadjuvant chemotherapy may be optimized via MRI guidance for the treatment of hormone receptor-negative/HER2-positive breast cancer.
ctDNA Monitoring is a Piece of the Puzzle in CRC Treatment
Holly Chitwood, DNP, FNP-C, AGACNP-BC, explains how circulating tumor DNA monitoring helps providers screen minimal residual disease in individuals with colorectal cancer.
CTX-009 Plus Paclitaxel Receives Fast Track Designation for Pretreated Biliary Tract Cancer
The FDA granted fast track designation to CTX-009 plus paclitaxel for pretreated metastatic or locally advanced biliary tract cancer.
Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses
Ryan Tamargo, NP, AONCP, discusses the launch of an online inflammatory breast cancer scoring system tool.
Trastuzumab Deruxtecan Enhances PFS in Metastatic HR+/HER2-Low Breast Cancer
Trastuzumab deruxtecan enhanced survival without disease progression compared with chemotherapy in HR-positive, HER2-low metastatic breast cancer after 1 or more lines of endocrine therapy.
ADCs Associated With Fatigue Among Patients With Breast Cancer
From journaling to delegating everyday tasks, nurses can teach patients how to cope with treatment-related fatigue.
Apalutamide/ADT Confers 100% Recurrence-Free Survival in High-Risk Prostate Cancer
TAR-200 Leads to Lasting Responses in BCG-Unresponsive Bladder Cancer
UGN-102 Produces Comparable Responses Regardless of Surgery in NMIBC Subset
Verbal Workflow for Tocilizumab Orders Results in More Timely CRS Intervention